American Red Cross: Celebrate Black History Month by Participating in a ‘Sleeves Up’ Campaign

February is Black History Month  – a time to honor the significant achievements of Black Americans while making an impact today. This year’s theme focuses on the importance of Black health and wellness. The American Red Cross is honoring the legacy of Dr. Charles Drew, an African American surgeon, and researcher who pioneered new methods for collecting, preserving, and distributing blood, as well as storing blood plasma for transfusion. We work to celebrate his advancements by putting a challenge out to the entire Georgia Region.

“Dr. Drew’s work with the Red Cross Blood Program helped save the lives of hundreds of thousands of people,” said Dee Dixon, CEO of Georgia’s Red Cross. “With blood transfusions remaining one of the most critical treatments for patients with chronic illnesses such as sickle cell, I invite Georgians everywhere to continue Dr. Drew’s lifesaving legacy by rolling up a sleeve to give blood during Black History Month.”

No bloodmobile or space is needed to answer this challenge, making it especially convenient for students and organizations to get involved. Simply create your campaign online, and send an invitation to your friends and family members anywhere in Georgia to join you in donating blood and saving lives.

Participants can visit  www.redcrossblood.org  to enter their zip code and find/book a convenient blood donation appointment in February or upcoming months.

Once participants are ready to roll up a sleeve, we want to see it! We invite all campaign blood donors to snap a picture and share it on social media using the hashtags:  #TeamUp4SickleCellGA & #BlackBloodDonorsNeeded . 

Calendar opportunities for launching an inspiring Sleeves Up Campaign during Black History Month / American Heart Month include:

  • African Heritage and Health Week – Feb. 1-7
  • Rosa Parks Day – Feb. 5
  • National Black HIV/AIDS Awareness Day – Feb. 7
  • National Donor Day – Feb. 14
  • Frederick Douglass Day – Feb. 14
  • National Black Girl Magic Day – Feb. 15
  • World Day of Social Justice – Feb. 20
  • Black Lives Matter Day – Feb. 26
  • Rare Disease Day – Feb. 28

Blood donations from everyone remain essential to the health of communities. However, African American donors play a critical role in meeting the need for blood – especially for those with sickle cell disease who often rely on closely matched blood products for regular transfusions. Individuals of all blood types are urged to make an appointment now to give blood or platelets in the weeks ahead by using the  Red Cross Blood DonorApp , visiting  RedCrossBlood.org , or calling  1 800-RED CROSS (1-800-733-2767) .

 As an extra thank-you during Black History Month, those who come to give in February will receive a $10  Amazon.com  Gift Card via email,  thanks to Amazon.

The Red Cross is currently providing free sickle cell trait screening on all donations from self-identified African American donors in addition to a free mini health screening with insights on pulse, blood pressure and hemoglobin levels.

About the American Red Cross:

The American Red Cross shelters, feeds, and provides emotional support to victims of disasters; supplies about 40 percent of the nation’s blood; teaches skills that save lives; provides international humanitarian aid; and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information, please visit  redcross.org  or  cruzrojaamericana.org .

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →
September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.
September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS